Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points
- 25 February 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 29 (8), 4185-4186
- https://doi.org/10.1007/s00520-021-06100-4
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western ItalyMedicina Oral Patología Oral y Cirugia Bucal, 2021
- Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysisSupportive Care in Cancer, 2020
- Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in GermanySupportive Care in Cancer, 2020
- Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysisSupportive Care in Cancer, 2019
- Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jawOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2018
- Rapid onset of osteonecrosis of the jaw in patients switching from bisphosphonates to denosumabOral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2018
- Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumabActa Clinica Belgica, 2018
- Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplementary data from the denosumab extension study?Supportive Care in Cancer, 2016
- Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancerSupportive Care in Cancer, 2015
- Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastasesAnnals of Oncology, 2011